🇺🇸 FDA
Pipeline program

KAI-7535

K7535-2101

Phase 2 small_molecule active

Quick answer

KAI-7535 for Obesity is a Phase 2 program (small_molecule) at Kailera Therapeutics with 2 ClinicalTrials.gov record(s).

Program details

Company
Kailera Therapeutics
Indication
Obesity
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials